| P/E (FY) | — | Sales (TTM) | $7.9M |
| Earnings (TTM) | -$354.3M | ROE | −73.70% |
| Net Margin | — | ROIC | — |
| Debt / Equity | 0.35 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor in Phase 3 targeting KIT mutations that drive systemic mastocytosis and advanced gastrointestinal stromal tumors. The pipeline also includes CGT4859, an FGFR2 inhibitor in Phase 1, plus the CGT4255 ErbB2 mutant program and CGT6297 PI3Ka program.
No price history for COGT — it is outside the redistributable backbone (BYOK data required), so price statistics are unavailable.
No return history for COGT, so risk analytics are unavailable.
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $6.56B | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.39B | 107.9 |
| PTCT | PTC THERAPEUTICS, INC. | $6.58B | 9.6 |
| XENE | Xenon Pharmaceuticals Inc. | $6.10B | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.09B | 86.8 |
| LGND | LIGAND PHARMACEUTICALS INC | $5.77B | 47.0 |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.30B | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.69B | — |
| ERAS | Erasca, Inc. | $5.51B | — |
| LQDA | Liquidia Corp | $7.72B | — |
| AMRN | AMARIN CORP PLC\UK | $5.39B |
| ORKA | Oruka Therapeutics, Inc. | $5.31B | — |